Melia Loskill is Vice President of Market Access at Autolus, with over 25 years of leadership in healthcare and biotechnology. She specializes in oncology and the commercialization of cell and gene therapies (CGT), having launched more than 15 products, including first-in-class cell therapies and next-generation CAR T. Her expertise spans pricing, payer marketing, contracting, government affairs, and policy development. Melia has driven innovative access solutions and managed markets strategies to accelerate adoption of advanced therapies. Previously, she held senior roles at Gamida Cell, Mesoblast, Celgene/Bristol Myers Squibb, and Novartis Oncology. Passionate about advancing patient access, she thrives on shaping the evolving CGT landscape.